Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, improves cardiovascular events (MI, stroke, HF) in Type 2 Diabetes and Chronic Kidney Disease (CKD) patients. Some risk factors for cardiovascular diseases (CVD), such as high blood glucose, blood pressure, serum cholesterol, and BMI, are also associated with CKD and type 2 diabetes. …
Read More »Sickle Cell Disease and Diabetes Mellitus
Is there a link between patients living with sickle cell disease and diabetes mellitus? African-Americans/ Black are the most affected by sickle cell disease (SCD). According to the US Department of Health and Human Services Office of Minority Health, this population also has the highest prevalence of obesity. Sickle cell …
Read More »Influence of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus
Sodium-glucose cotransporter 2 inhibitors lower the risk of hospitalization in heart failure and cardiovascular death… The SIMPLE trial examined the effects of empagliflozin on myocardial flow reserve, showing microvascular perfusion in individuals with type 2 diabetes with high CVD risk. The SIMPLE trial is a single-center, double-blind, randomized clinical trial …
Read More »Effectiveness of blood glucose control protocol for open-heart surgery patients
Controlling your blood sugar is more important than you think in the ICU… Glycemic control for patients is considered one of the most important factors when treating patients in an intensive care unit. Hyperglycemia statistically is deemed to be related to increased mortality and or morbidity. It is also an …
Read More »Canagliflozin Effects on NT-proBNP and Heart Failure
Which subgroup of patients with type 2 diabetes and heart failure is more beneficial from treatment with canagliflozin? Patients with type 2 diabetes are at risk for many cardiovascular diseases, including heart failure. In a cohort study published by Nichols et al., patients with type 2 diabetes are more likely …
Read More »DPP-4 Inhibitors Vs. Sulphonylureas As Add-On to Metformin – Assessing CV Outcomes in Type 2 Diabetes
New retrospective study results compare the two most largely prescribed antidiabetic medication classes in addition to metformin, to determine the impact on the incidence of CV events in patients with T2DM. Dipeptidyl-peptidase-4 inhibitors (DPP-4i) and sulphonylureas (sulfonylureas in the US) (SU) are two of the most prescribed medication to date …
Read More »Type 2 Diabetes: The Impact of Vision and Hearing Impairments on CV Risk Outcomes and Mortality
A comprehensive study reveals the importance of ophthalmologic and otologic care in patients with T2DM due to the association of increased risks for cardiovascular events in those with a decline in vision and hearing abilities. It is known that patients with type 2 diabetes mellitus (T2DM) have an increased risk …
Read More »Physical Activity: a Cheaper and Better Way to Save Lives in Patients with Diabetes
Effective preventive strategies are needed to reduce cardiovascular disease, the leading cause of mortality and morbidity globally.
Read More »Lipid Profiling Can Predict the Risk of Diabetes and CVD Years Before Onset
The analysis of lipid profiling in the prediction of risk of developing type 2 diabetes and cardiovascular diseases can aid in recommending lifestyle changes and diet before the development of the diseases.
Read More »Can Caffeine be the Key to Fighting CVD?
Studies have found that average levels of moderate caffeine intake are related to lower cardiovascular risk.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.